Telix Pharmaceuticals Ltd (ASX: TLX) shares are on the move on Wednesday morning.
At the time of writing, the ASX radiopharmaceuticals stock is down 7.5% to $14.28.
As a comparison, the ASX 200 index is trading 0.25% higher in morning trade today.
Image source: Getty Images
Why are Telix shares falling today?
The company's shares are under pressure following the announcement of a large convertible bond offering due in 2031.
According to the release, Telix has raised US$600 million from the convertible notes offering.
These notes can be converted into ordinary Telix shares at a future date, which introduces the potential for dilution if conversion occurs.
Management noted that the proceeds will primarily be used to refinance its existing convertible bonds due 2029, with any excess funds directed toward general corporate purposes.
The bonds are expected to carry a relatively low coupon of between 1.50% and 1.75% and will be issued with a conversion price of US$13.85 (~A$19.55), which is a premium of approximately 37.5% to the current share price.
While the company described the transaction as cost-effective financing, the combination of potential dilution and associated hedging activity appears to be weighing on sentiment.
Telix's managing director and group CEO, Dr. Christian Behrenbruch, said:
The refinance of the existing Convertible Bonds represents our proactive approach to capital management. The new Convertible Bonds will continue to provide the business with cost effective financing.
The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.
Investor presentation
Alongside the announcement, Telix also released an updated investor presentation, which largely reiterated previously disclosed performance and outlook details.
The presentation highlights that the company generated group revenue of US$230 million in the first quarter of 2026, representing an 11% increase on the previous quarter and a 23.7% jump on the prior corresponding period.
Looking ahead, Telix continues to guide to FY 2026 revenue in the range of US$950 million to US$970 million. This will be supported by growth in its Precision Medicine business and contributions from its radiopharmacy operations.
Its research and development guidance range remains US$200 million to US$240 million.
And this appears to be money well spent. The company pointed to progress across its pipeline, including multiple late-stage clinical programs and upcoming regulatory milestones.
It also spoke about its significant market opportunity in the US market. Management estimates that it has a US$32 billion addressable market across its Precision Medicine and Therapeutics pipeline.
